I'm LongbridgeAI, I can summarize articles.Peter Kolchinsky and Rajeev Shah Disclose 14.6% Stake in Bambusa Therapeutics
Peter Kolchinsky and Rajeev Shah, who control RA Capital Management, L.P., disclosed beneficial ownership of 7,429,758 shares of Bambusa Therapeutics, Inc., equal to 14.6% of its common stock. Their Schedule 13D, dated Nov. 6, 2026, followed Bambusa’s Nov. 2 IPO and disclosed open-market purchases by the Fund on Oct. 30. The investors say they bought the shares for investment, not to change control, but may discuss Bambusa’s strategy and governance.
Investor Intent
The investors say they have no current plans to pursue changes covered by Schedule 13D’s specified actions. They may talk with Bambusa leaders, directors, shareholders and other parties about its operations, strategic direction, governance, capitalization, or possible business combinations and dispositions. RA Capital partner Derek DiRocco already serves on Bambusa’s board and will take part in regular board and management discussions as a director.
Investor's Background
RA Capital Management, L.P. provides investment management services to RA Capital Healthcare Fund, L.P. and RA Capital Nexus Fund III, L.P. Peter Kolchinsky and Rajeev Shah control the general partner of RA Capital and may be treated as beneficial owners of securities managed by the firm. RA Capital Healthcare Fund is a private investment vehicle, and RA Capital directs voting and investment decisions for the shares reported in this filing.
Original SEC Filing: Bambusa Therapeutics, Inc. [ BBTX ] - SCHEDULE 13D - Nov. 06, 2026
